https://fungimap.org.au/galleries/ray-palmer/p2101960-psilocybe-cubensis-3-2/
https://fungimap.org.au/galleries/ray-palmer/p2101960-psilocybe-cubensis-3-2/

BACKGROUND BRIEFING: Psychedelic therapies available in Australia from July 1st

Embargoed until: Publicly released:
Not peer-reviewed: This work has not been scrutinised by independent experts, or the story does not contain research data to review (for example an opinion piece). If you are reporting on research that has yet to go through peer-review (eg. conference abstracts and preprints) be aware that the findings can change during the peer review process.

*Recording now available* Australia's Therapeutic Goods Administration (TGA) announced earlier this year that authorised psychiatrists will be allowed to prescribe two different psychedelic substances for specific mental health conditions from July 1st. The drugs in question are 3,4-Methyl​enedioxy​methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD), and psilocybin, the active ingredient in magic mushrooms, for treatment-resistant depression. These drugs are best known for recreational and illegal use, and the change involves their re-scheduling from the strictest controlled category, Schedule 9 (Prohibited Substances), to Schedule 8 (Controlled Drugs), but only for medical use. There's been a lot of buzz around these therapies in the media, and some promising trial results, but how much do we really know about how they work and their effectiveness in real-world settings? Join us for this online briefing, when three Australian experts who are involved in researching the use and implementation of these therapies will discuss the changes and the future of psychedelic therapies in Australia, as well as taking questions from journalists.

Organisation/s: Australian Science Media Centre, University of South Australia, The University of Melbourne, Swinburne University of Technology, Goodmind Therapeutics

Funder: N/A

Media release

From: Australian Science Media Centre

Speakers:

  • Dr Mike Musker is an Enterprise Fellow in the Mental Health and Suicide Prevention Research and Education Group at the University of South Australia (UniSA). Mike is on the Medical Advisory Board at Goodmind Therapeutics - a clinic offering psychedelic-assisted therapy.
  • Dr Daniel Perkins is Co-Executive Director of the Psychae Institute, a Senior Research Fellow in the School of Population and Global Health at the University of Melbourne, and an Adjunct Associate Professor from the Centre for Mental Health at Swinburne University
  • Scott Kelly is Co-founder of Goodmind Therapeutics - a clinic offering psychedelic-assisted therapy. He is a practicing clinical psychology registrar / somatic psychotherapist

Date: Thu 29 June 2023
Start Time: 10:00am AEST
Duration: Approx 45 min 
Venue: Online - Zoom

Attachments:

Note: Not all attachments are visible to the general public

News for:

Australia
NSW
VIC
SA

Media contact details for this story are only visible to registered journalists.